<DOC>
	<DOCNO>NCT00034645</DOCNO>
	<brief_summary>This trial high risk patient determine safety , tolerance efficacy posaconazole ( POZ ) vs. fluconazole prophylaxis development invasive fungal infection ( IFI ) .</brief_summary>
	<brief_title>Prophylaxis Trial High Risk Allogenic Stem Cell Transplant Recipients With Graft v . Host Disease</brief_title>
	<detailed_description>This study design determine safety , tolerance efficacy POZ use prophylaxis IFI high-risk subject Grade II-IV acute graft vs. host disease ( GVHD ) extensive chronic GVHD . The primary objective ass efficacy SCH56592 v fluconazole prevent proven probable IFI within time period randomization 16 week start treatment study drug .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Hematopoietic progenitor cell transplant subject chronic Grade IIIV acute GVHD treat high dose immunosuppressive therapy . One follow subject 's prior immunosuppressive regimen : 1. least 1mg per kg per day methylprednisolone equivalent , 2 . Antithymocyte globulin ( ATG ) therapy acute GVHD , 3 . Tacrolimus , mycophenolate mofetil , steroidsparing immunosuppressive regimen .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Allogenic Stem cell transplantation</keyword>
	<keyword>Fungal infection</keyword>
</DOC>